| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Ullevaal University Hospital University Hospital, Aker Pfizer |
| Information provided by: | Ullevaal University Hospital |
| ClinicalTrials.gov Identifier: | NCT00222196 |
Purpose
Background: Percutaneous transluminal angioplasty (PTA) has been popularized as a simple, effective and cheap treatment achieving 50-70% symptomatic patency rates in patients with peripheral occlusive disease.. However, the fact remains that the indication for performing PTA are still more based on opinions than on scientific data.
The purpose of the trial was to randomize patients primarily referred for intermittent claudication into two groups: One group was offered conservative treatment; the other group was offered conservative treatment combined with PTA.
Primary outcome: The patient quality of life. Secondary outcome:Pain-free walking distance; pain-score; death; amputation; changes in relevant biomarkers
| Condition | Intervention |
|
Peripheral Vascular Disease |
Procedure: lifestyle, PTA |
| MedlinePlus related topics: | Angioplasty Peripheral Vascular Diseases Vascular Diseases |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
| Official Title: | Oslo Balloon Angioplasty Versus Conservative Treatment |
Eligibility
| Ages Eligible for Study: | up to 75 Days |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations More Information
| Study ID Numbers: | OBACT |
| First Received: | September 13, 2005 |
| Last Updated: | December 29, 2005 |
| ClinicalTrials.gov Identifier: | NCT00222196 |
| Health Authority: | Norway: The National Committees for Research Ethics in Norway |
|
|
|
|
